Gary S. Hogge

1.3k total citations · 1 hit paper
12 papers, 937 citations indexed

About

Gary S. Hogge is a scholar working on Genetics, Immunology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Gary S. Hogge has authored 12 papers receiving a total of 937 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 5 papers in Immunology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Gary S. Hogge's work include Virus-based gene therapy research (5 papers), Immunotherapy and Immune Responses (3 papers) and Cancer Research and Treatments (2 papers). Gary S. Hogge is often cited by papers focused on Virus-based gene therapy research (5 papers), Immunotherapy and Immune Responses (3 papers) and Cancer Research and Treatments (2 papers). Gary S. Hogge collaborates with scholars based in United States, Australia and Canada. Gary S. Hogge's co-authors include Ronald Goldblum, Jean‐Frédéric Colombel, Remo Panaccione, Martin E. Sanders, William J. Sandborn, Stephen B. Hanauer, Paul Rutgeerts, Stefan Schreiber, Brian G. Feagan and Stephan R. Targan and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Gary S. Hogge

11 papers receiving 902 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

2005 688 citations William J. Sandborn, Jean‐Frédéric Colombel et al. New England Journal of Medicine profile →

Peers

Gary S. Hogge

GENET

EPIDE

IMMUN

SURGE

PRM

Atar Lev Israel

Madelyn R. Schmidt United States

Pradip N. Akolkar United States

Cinzia Mazza Italy

Laurence Ménard United States

Hamoud Al‐Mousa Saudi Arabia

Francesca Mazzetta Italy

Lin Radigan United States

H D Ochs United States

Jennifer W. Leiding United States

Atar Lev Israel

Gary S. Hogge

308 ×0.5

GENET

184 ×0.5

EPIDE

729 ×2.2

IMMUN

48 ×0.3

SURGE

158 ×1.2

PRM

Citations per year, relative to Gary S. Hogge Gary S. Hogge (= 1×) peers Atar Lev

Countries citing papers authored by Gary S. Hogge

Since Specialization

Citations

This map shows the geographic impact of Gary S. Hogge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary S. Hogge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary S. Hogge more than expected).

Fields of papers citing papers by Gary S. Hogge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary S. Hogge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary S. Hogge. The network helps show where Gary S. Hogge may publish in the future.

Co-authorship network of co-authors of Gary S. Hogge

This figure shows the co-authorship network connecting the top 25 collaborators of Gary S. Hogge. A scholar is included among the top collaborators of Gary S. Hogge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary S. Hogge. Gary S. Hogge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Rana, Sabhya, David B. Weiner, Armin Blesch, et al.. (2025). Lessons Learned and Recommendations from a SCOPE Spinal Cord Injury Neurorestorative Clinical Trials Update. Neurotrauma Reports. 6(1). 210–231. 1 indexed citations

2.

Riemann, Christopher D., Eyal Banin, Adiel Barak, et al.. (2021). Phase I/IIa Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD): Interim Results. 62(8). 3316–3316. 2 indexed citations

3.

Riemann, Christopher D., Eyal Banin, Adiel Barak, et al.. (2017). Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results. 58(7). 2320–2320. 14 indexed citations

4.

Varghese, Santosh T., Gary S. Hogge, Gary Bloomgren, et al.. (2012). Mo1050 Natalizumab use in Patients With Crohn's Disease and Relapsing Multiple Sclerosis: Updated Utilization and Safety Results From the Touch(r) Prescribing Program, the Pregnancy Registry, and the INFORM and TYGRIS Studies. Gastroenterology. 142(5). S–581.

5.

Jaros, Mark, Simonetta Mocci, Ted Yednock, et al.. (2011). Evaluation of the Incidence of Anti-JC Virus Antibodies in a Cohort of Natalizumab-Treated Patients. Gastroenterology. 140(5). S–768. 1 indexed citations

6.

Phillips, Brenda, Barbara E. Powers, William S. Dernell, et al.. (2009). Use of Single-Agent Carboplatin as Adjuvant or Neoadjuvant Therapy in Conjunction With Amputation for Appendicular Osteosarcoma in Dogs. Journal of the American Animal Hospital Association. 45(1). 33–38. 98 indexed citations

7.

Mahadevan, Uma, et al.. (2008). Natalizumab Use During Pregnancy. The American Journal of Gastroenterology. 103. S449–S450. 12 indexed citations

8.

Sandborn, William J., Jean‐Frédéric Colombel, Brian G. Feagan, et al.. (2005). Natalizumab Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine. 353(18). 1912–1925. 688 indexed citations breakdown →

9.

Chauvet, Anne E., et al.. (1999). Vertebrectomy, Bone Allograft Fusion, and Antitumor Vaccination for the Treatment of Vertebral Fibrosarcoma in a Dog. Veterinary Surgery. 28(6). 480–488. 12 indexed citations

10.

Hogge, Gary S., J K Burkholder, J Culp, et al.. (1999). Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Therapy. 6(1). 26–36. 38 indexed citations

11.

Hogge, Gary S., J K Burkholder, J Culp, et al.. (1998). Development of Human Granulocyte-Macrophage Colony-Stimulating Factor-Transfected Tumor Cell Vaccines for the Treatment of Spontaneous Canine Cancer. Human Gene Therapy. 9(13). 1851–1861. 45 indexed citations

12.

Chandler, Laura J., Gary S. Hogge, M. Endres, et al.. (1991). Reassortment of La Crosse and Tahyna bunyaviruses in Aedes triseriatus mosquitoes. Virus Research. 20(2). 181–191. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact